Healthcare · Operations & Throughput
The Best AI Workflow for Finance Back Office in Pharmaceuticals
We design, build, and run AI-native finance back office for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native finance back office for pharmaceuticals is a phased engagement (Discovery 3 weeks → Build 8 weeks → Run continuous (regulated industry)) that ships a production workflow on top of CRM and medical information systems, moves close cycle time by −73% against the pharmaceuticals baseline, and is operated under operations & throughput governance from day one.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Finance Back Office
- Intent cluster
- Operations & Throughput
- Primary KPI
- close cycle time, exception rate, invoice processing cost, and forecast variance
- Top benchmark
- Cost per transaction (fully loaded): $14.20 → $3.85 (−73%)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 3 weeks → Build 8 weeks → Run continuous (regulated industry)
- Team size
- 2 senior delivery + 1 part-time reviewer trainer
- Discovery price
- $6k · 2-week sprint
- Build price
- $20k–$28k · 6-10 weeks
Primary outcome
reduce manual finance work without losing control
What we ship
invoice workflows, reconciliation assistant, variance explanations, and approval controls
KPIs we report on
close cycle time, exception rate, invoice processing cost, and forecast variance
Why Pharmaceuticals teams hire us for this
In pharmaceuticals, reduce manual finance work without losing control is constrained by the speed at which experienced operators can review context, weigh tradeoffs, and act. AI-native finance back office unblocks the throughput ceiling without removing the operator from the loop — the system handles intake, retrieval, drafting, and first-pass review; the operator owns judgment, exception handling, and final approval.
World Economic Forum's Lighthouse Network data on pharmaceuticals operations shows that the fastest productivity gains come from automating the work between systems, not inside any single system. AI-native delivery sits in that gap.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of finance back office in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Cost per transaction (fully loaded) Includes AI inference cost, reviewer time, and infra amortization | $14.20 | $3.85 | −73% |
Time-to-onboard new operator AI assistant handles the long tail of edge cases that previously required senior coaching | 8 weeks | 2 weeks | −75% |
Cycle time per transaction Measured on labelled production samples; excludes outliers >2σ | 47 min median | 8 min median | −83% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
On finance back office for pharmaceuticals, we operate on a fixed weekly cadence: Monday metrics review (KPIs vs baseline, edge cases sampled), Wednesday prompt + retrieval refresh (new patterns folded in), Friday reviewer-queue audit (calibration drift, false-positive rate). The cadence is the deliverable; the prompts are the artefacts.
What we build inside the workflow
The visible deliverable of a Build engagement for finance back office is the working workflow: invoice workflows, reconciliation assistant, variance explanations, and approval controls. The invisible deliverables — labelled test set, prompt repository, evaluation harness, audit log infrastructure, runbook, exit plan — are what makes the workflow defensible 6 and 12 months later. We document and hand over all of them at the close of Build.
Reference architecture
4-layer AI-native workflow for operations & throughput
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Operations & Throughput →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for finance back office in pharmaceuticals.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | −75% |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Operations engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$6k
2-week sprint
Phase 2 · Build
$20k–$28k
6-10 weeks
Phase 3 · Run
$2.5k–$4k / mo
optional, hourly bank also available
~$32k–$58k typical year 1 (60% take the run option for ~6 months)
Workflow redesign, system integration, governance, and weekly operating cadence during Run.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for finance back office
Reference inputs below are typical for pharmaceuticals teams in the operations cluster. Adjust them to match your situation.
Projected
Current monthly cost
$56,000
AI-native monthly cost
$18,520
Annual savings
$449,760
67% cost reduction · ~2,601 operator-hours freed / month
Governance and risk controls
Risk in pharmaceuticals comes from three failure modes: the model is wrong, the source data is wrong, or the workflow allows the wrong action. We design for each mode separately — evaluation harness for model error, source curation and freshness for data error, allow-listed tool calls and approval queues for action error. Each has a defined owner and a measurable SLA.
How we report ROI
ROI on finance back office shows up in two timeframes for pharmaceuticals: immediate (cycle time, throughput, error rate — visible within 30 days of Run) and structural (operating model maturity, knowledge capture, team capacity unlock — visible at 6-12 months). The first justifies the engagement; the second is what changes the business.
Common pitfall & mitigation
The failure mode we see most often on AI-native finance back office engagements in pharmaceuticals contexts.
Integration debt with legacy systems
ERP/SAP integration is treated as 'last step' and blocks production
Integration scoped during Discovery; mock-then-real pattern during Build
Build internally or work with us
The strongest pattern we see in pharmaceuticals is blended: we design and launch the first production workflow, your internal team owns data access, security review, and stakeholder alignment. Over 6-12 months, your team takes over Run while we move to the next workflow. The exit plan is part of the Statement of Work.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from pharmaceuticals, not only generic test prompts.
- Ask how we will move close cycle time, exception rate, invoice processing cost, and forecast variance within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native finance back office in pharmaceuticals is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate finance back office in pharmaceuticals with AI?+
We map the existing finance back office workflow inside pharmaceuticals, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your CRM, medical information systems, safety databases, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure close cycle time, exception rate, invoice processing cost, and forecast variance, and improve it weekly.
What does it cost to automate finance back office for a pharmaceuticals company?+
Three phases, billed separately. Discovery sprint: $6k (2-week sprint). Build engagement: $20k–$28k (6-10 weeks). Run retainer: $2.5k–$4k / mo (optional, hourly bank also available). ~$32k–$58k typical year 1 (60% take the run option for ~6 months). Workflow redesign, system integration, governance, and weekly operating cadence during Run.
What is the best AI agent for finance back office in pharmaceuticals?+
There is no single "best" off-the-shelf agent for finance back office in pharmaceuticals — the right architecture depends on your CRM setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for CRM and medical information systems integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI finance back office for pharmaceuticals?+
A thin-slice deployment in 2-week sprint after Discovery, with real pharmaceuticals data and real reviewers. The full Build phase runs 6-10 weeks. By day 90, close cycle time, exception rate, invoice processing cost, and forecast variance is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent pharmaceuticals workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How fast does AI finance back office get into production for pharmaceuticals?+
We aim for a thin-slice in production by week 6, with real data, real edge cases, and real reviewers. close cycle time, exception rate, invoice processing cost, and forecast variance is instrumented from day one, and we report against baseline weekly during Run.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- Helpful, reliable, people-first content — Google Search Central
- Responsible Scaling Policy — Anthropic
- Operations Excellence Through AI — BCG
- Future of Work: Operations — Deloitte Insights
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Concepts on this page:
AI workflow·Thin slice·Reviewer queue·Evaluation harness·Tool use·Audit logFull glossary →Start the engagement
Book a discovery call for Pharmaceuticals
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.